Biomedical Engineering Reference
In-Depth Information
19. Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku
compete for repair of DNA double strand breaks by distinct NHEJ
pathways.
2006; 34(21): 6170-6182.
20. Easton D, Ford D, Peto J. Inherited susceptibility to breast cancer.
Cancer Surv
Nucleic Acids Res
1993; 18: 95-113.
21. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton
DF,
BRCA1 and BRCA2 mutations in a population-based study of
male breast cancer.
et al.
2002; 4(1): R2.
22. Johns Hopkins Pathology. Ovarian Cancer. Johns Hopkins Pathology;
Available from:
http://www.ovariancancer.jhmi.edu/hereditary.cfm.
HealthProfessional/page2. Prostate Cancer Susceptibilty Loci.
Breast Cancer Res
BRCA1
and BRCA2: Cancer Risk and Genetic Testing.
25. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J,
et
al.
Incidence and outcome of BRCA mutations in unselected patients
with triple receptor-negative breast cancer.
Clin Cancer Res
2011 Mar
1; 17(5): 1082-1089.
26. Leegte B, van der Hout AH, Deffenbaugh AM, Bakker MK, Mulder IM,
ten Berge A,
Phenotypic expression of double heterozygosity for
BRCA1 and BRCA2 germline mutations.
et al.
J Med Genet
2005 Mar; 42(3):
e20.
27. Genetics M. Myriad Genetics
2010.
28. Tommasi S. BRCA1 mutations and polymorphisms in a hospital-based
consecutive series of breast cancer patients from Apulia, Italy.
BRCA test kit
Mutat
2005 2005; 587: 359-405.
29. Society AC. National Guideline Clearinghouse. 2007.
30. James PA, Doherty R, Harris M, Mukesh BN, Milner A, Young MA,
Res
et
al.
Optimal selection of individuals for BRCA mutation testing: a
comparison of available methods.
J Clin Oncol
2006 Feb 1; 24(4): 707-
715.
31. van Harssel JJ, van Roozendaal CE, Detisch Y, Brandao RD, Paulussen
AD, Zeegers M,
Efficiency of BRCAPRO and Myriad II mutation
probability thresholds versus cancer history criteria alone for BRCA1/2
mutation detection.
et al.
2010 Jun; 9(2): 193-201.
32. Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut
AI. Effect of prevention strategies on survival and quality-adjusted
survival of women with BRCA1/2 mutations: an updated decision
analysis.
Fam Cancer
J Clin Oncol
2002 May 15; 20(10): 2520-2529.
